GlassScriptPhysician profile
Zeev W Weitz
NPI 1285660043
$13,891.96
in general payments reported to CMS, 2019-2025
59 companies · $2,549 in 2025
The $2,549 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,005 · 2020: $721 · 2021: $1,205 · 2022: $2,267 · 2023: $2,534 · 2024: $2,611 · 2025: $2,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,509 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,509.08 |
| Education | $184.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,399.69 | 2019-2025 | Rinvoq, Dalvance, Skyrizi |
| Amgen INC. | $1,879.87 | 2019-2025 | Evenity, Enbrel, Prolia |
| Janssen Biotech, INC. | $1,625.09 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $1,230.31 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $951.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $860.42 | 2019-2025 | Saphnelo, Evusheld, Fasenra |
| Glaxosmithkline, LLC. | $822.27 | 2019-2025 | Benlysta, Trelegy Ellipta |
| Lilly USA, LLC | $458.96 | 2019-2025 | Taltz, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $444.46 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Viiv Healthcare Company | $290.36 | 2019-2025 | Rukobia, Apretude, Dovato |
| Exact Sciences Corporation | $178.75 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $173.05 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.89 | 2019-2024 | Xifaxan |
| Organon LLC | $150.87 | 2023-2025 | Hadlima, Renflexis |
| Genzyme Corporation | $145.45 | 2024-2025 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeev Weitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.